**Background of LXN Antibodies**
LXN (latexin) is a 25-kDa endogenous inhibitor of metallocarboxypeptidases, notably carboxypeptidase A (CPA), and is structurally characterized by a cystatin-like fold. Initially identified in rodents, LXN is evolutionarily conserved and plays roles in inflammation, cellular differentiation, and tissue homeostasis. Its expression is detected in diverse tissues, including the nervous, immune, and cardiovascular systems.
Research highlights LXN's dual role in cancer biology, acting as a tumor suppressor in some contexts (e.g., inhibiting proliferation in breast and colorectal cancers) while promoting aggressiveness in others. It also regulates stem cell populations, such as hematopoietic and neural stem cells, influencing self-renewal and differentiation.
LXN antibodies are essential tools for investigating its expression patterns, interactions, and functions. Due to interspecies sequence variations (e.g., ~80% homology between human and mouse LXN), species-specific antibodies are developed for precise detection. These antibodies enable applications like Western blotting, immunohistochemistry, and ELISA, aiding studies on LXN's involvement in diseases, including cancer, neurodegeneration, and fibrosis. Recent studies also explore LXN's potential as a therapeutic target or biomarker, driving demand for high-affinity, validated antibodies.
Overall, LXN antibodies are pivotal in unraveling the protein's complex roles in physiology and pathology.